Novartis AG, a leading global healthcare company headquartered in Switzerland (CH), has established itself as a pioneer in the pharmaceutical industry since its founding in 1996. With a strong presence in key operational regions including North America, Europe, and Asia, Novartis focuses on innovative medicines, generics, and eye care products. The company is renowned for its commitment to research and development, producing unique therapies in areas such as oncology, cardiology, and immunology. Notable achievements include the development of groundbreaking treatments that have transformed patient care. As a top player in the pharmaceutical market, Novartis continues to drive advancements in healthcare, making significant contributions to global health and well-being.
How does Novartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Novartis's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Novartis reported total carbon emissions of approximately 4,587,300,000 kg CO2e, with Scope 1 emissions at about 207,000,000 kg CO2e, Scope 2 emissions at approximately 30,000,000 kg CO2e (market-based), and a significant Scope 3 contribution of around 4,350,300,000 kg CO2e. This represents a decrease from 2023, where total emissions were about 4,868,900,000 kg CO2e, with Scope 1 at 251,100,000 kg CO2e and Scope 3 at 4,573,700,000 kg CO2e. Novartis has set ambitious climate commitments, aiming for carbon neutrality in its own operations (Scopes 1 and 2) by 2025. The company has achieved a 19% reduction in Scope 1 and 2 emissions year-on-year, amounting to a total reduction of 63% compared to a 2016 baseline. Furthermore, Novartis is committed to reducing absolute Scope 1, 2, and 3 GHG emissions by 35% by 2030 from the same baseline year. Looking ahead, Novartis aims to achieve net-zero emissions across its entire value chain by 2040, aligning with the goals of the Paris Agreement to limit global temperature rise to 1.5°C. The company has also pledged to reduce absolute Scope 1 and 2 emissions by 90% by 2030 from a 2022 base year, alongside a 42% reduction in Scope 3 emissions within the same timeframe. These initiatives reflect Novartis's commitment to sustainability and responsible environmental stewardship.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2014 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.